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Cardiac hypertrophy is a distinguished fea-
ture of several physiological and patho-
logical remodeling (Frey et al., 2004).
Pathological hypertrophy is commonly
seen in patients with heart injury or stress,
such as myocardial infarction, hyper-
tension, and valve disease (Frey et al.,
2004). Physiological hypertrophy is typ-
ically induced by exercise or pregnancy.
Interestingly, physiological hypertrophy is
generally accepted as an adaptive benefi-
cial response while pathological hypertro-
phy can ultimately decompensate to heart
failure, a common, costly, disabling, and
deadly disease. Thus, dissecting the mech-
anisms for physiological hypertrophy will
help identify novel effective therapies for
a large spectrum of cardiovascular dis-
eases (Da Costa Martins and De Windt,
2012).
Distinct underlying signaling path-
ways for physiological and pathological
hypertrophy have been identified (Maillet
et al., 2013). The classic pathway for
physiological hypertrophy is IGF-1/PI3K
(p110a)/Akt1 while the key one for
pathological hypertrophy is AngII (ET-
1)/Gaq/Calcineurin/NFAT (Maillet et al.,
2013). MicroRNAs (miRNAs, miRs) are
a novel class of non-coding RNAs with
20–24 length of base, which posttran-
scriptional regulates gene expression
via base-pairing with complementary
sequences within mRNA (Xiao et al.,
2012). It is estimated that over 1000
miRNAs were encoded by the human
genome. Individual miRNAs can reg-
ulate several target genes while one
gene can also be regulated by several
miRNAs. Being a center player of gene
regulation, miRNAs participate in many
essential biological processes, including
proliferation, differentiation, apoptosis,
necrosis, autophagy, and stress responses
(Xiao et al., 2012; Kumarswamy and
Thum, 2013). Due to these multiple roles,
it is naturally that miRNAs are critical
in the development of various heart dis-
eases, such as hypertrophy, heart failure,
acute myocardial infarction, and arrhyth-
mia (Xiao et al., 2011; Kumarswamy and
Thum, 2013). In addition, circulating
miRNAs have also been indicated to be
promising biomarkers for cardiovascular
diseases (Xu et al., 2012). Among them,
pathological hypertrophy is the most
widely studied one. Accumulating evi-
dence has indicated that a lot of miRNAs
such as miR-1, miR-133, miR-26, miR-9,
miR-98, miR-29, miR-199a, miR-199b,
miR-208, miR-23a, miR-499, miR-21,
and mir-19b contribute to pathological
hypertrophy (Da Costa Martins and De
Windt, 2012). Some distinguished reviews
have summarized it in detail (Da Costa
Martins and DeWindt, 2012; Ellison et al.,
2012).
Unlike pathological hypertrophy, only
a little studies described how miRNAs
response to physiological hypertro-
phy (Soci et al., 2011; Diniz et al.,
2013). It has been reported that miR-
1, miR-133, mir-29c, miR-27a, mir-27b,
and miR-143 response to physiologi-
cal hypertrophy (Soci et al., 2011; Da
Costa Martins and De Windt, 2012;
Ellison et al., 2012). However, these
miRNAs are either compensatory or
lack of direct evidence for regulating
cell size. Thus, these results might only
set the beginning of filling the gap in
miRNAs and physiological hypertrophy.
Although these studies have suggested
some potential roles of miRNAs in phys-
iological hypertrophy, more functional
studies are highly needed to establish
miRNAs as contributors for physiological
hypertrophy.
Traditionally, the adult mammalian
heart is recognized as a post-mitotic
organ with no regenerative capacity for
cardiomyogenesis (Rosenzweig, 2012).
Recently, resident endogenous cardiac
stem-progenitor cells (eCSCs) in the adult
heart challenged this dogma (Rosenzweig,
2012). Moreover, adult cardiomyocytes
have also been reported to proliferate in
response to specific stimuli (Rosenzweig,
2012). Two studies regarding physiologi-
cal hypertrophy are of great importance
(Boström et al., 2010; Waring et al., 2012).
A transcriptional factor named CEBPB
has been found to be down-regulated with
exercise and reduction of CEBPB induces
cardiomyocyte hypertrophy and prolifera-
tion (Boström et al., 2010). Further studies
show that CEBPB promotes cardiomy-
ocyte proliferation via increasing CITED4
(Boström et al., 2010). This study indicates
that besides the generally accepted idea
that physiological hypertrophy is solely
due to the hypertrophy of existing car-
diomyocytes, physiological hypertrophy
also has the phenotype of new cardiomy-
ocytes formation (Boström et al., 2010).
A more recent study shows that c-Kit
positive eCSCs increases their number
and activated state in exercise-induced
physiological hypertrophy, indicating
that c-Kit positive eCSCs might be a
source of new cardiomyocyte formation
(Waring et al., 2012). Therefore, myocyte-
restricted lineage tracing studies are highly
needed to definitively unravel this ques-
tion. Anyway, both studies indicate that
it is necessary to check miRNAs roles in
promoting new cardiomyocyte formation
either in cardiomyocytes or in eCSCs in
physiological hypertrophy.
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With the strategies for checking
myocyte hypertrophy and new cardiomy-
ocyte formation, the miRNA basis of
physiological hypertrophy will be revealed,
which will help develop a miRNA-based
therapy for heart failure.
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